INNOVIVA, INC. Gain (Loss) on Investments
INNOVIVA, INC. (INVA) reported Gain (Loss) on Investments of $130.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnInvestments · last filed 2022-11-09
- INNOVIVA, INC. gain (loss) on investments for the quarter ending 2022-09-30 was $130.00K, a 99.61% decline year-over-year.
- INNOVIVA, INC. gain (loss) on investments for the quarter ending 2022-06-30 was -$58.60M, a 229.32% decline year-over-year.
- INNOVIVA, INC. gain (loss) on investments for the quarter ending 2022-03-31 was -$9.41M, a 117.10% decline year-over-year.
- INNOVIVA, INC. gain (loss) on investments for the quarter ending 2021-12-31 was -$42.94M, a 489.26% decline year-over-year.
- INNOVIVA, INC. gain (loss) on investments for fiscal 2021 was $91.03M, a 81.06% increase from fiscal 2020.
- INNOVIVA, INC. gain (loss) on investments for fiscal 2020 was $50.28M.
- INNOVIVA, INC. gain (loss) on investments for fiscal 2019 was $0.00.
- INNOVIVA, INC. gain (loss) on investments for fiscal 2018 was $0.00.
| Period end | Gain (Loss) on Investments 3 month | Gain (Loss) on Investments 6 month | Gain (Loss) on Investments 9 month | Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2022-09-30 | $130.00K 10-Q · filed 2022-11-09 | -$58.47M derived: sum of 2 quarters · filed 2022-11-09 | -$67.88M 10-Q · filed 2022-11-09 | -$110.82M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | -$58.60M 10-Q · filed 2022-07-27 | -$68.01M 10-Q · filed 2022-07-27 | -$110.95M derived: sum of 3 quarters · filed 2022-07-27 | -$77.34M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-03-31 | -$9.41M 10-Q · filed 2022-05-05 | -$52.35M derived: sum of 2 quarters · filed 2022-05-05 | -$18.74M derived: sum of 3 quarters · filed 2022-11-09 | $26.57M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-12-31 | -$42.94M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | -$9.33M derived: sum of 2 quarters · filed 2022-11-09 | $35.98M derived: sum of 3 quarters · filed 2022-11-09 | $91.03M 10-K/A · filed 2022-03-17 |
| 2021-09-30 | $33.61M 10-Q · filed 2022-11-09 | $78.93M derived: sum of 2 quarters · filed 2022-11-09 | $133.97M 10-Q · filed 2022-11-09 | $145.00M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $45.31M 10-Q · filed 2022-07-27 | $100.36M 10-Q · filed 2022-07-27 | $111.39M derived: sum of 3 quarters · filed 2022-07-27 | $82.02M derived: sum of 4 quarters · filed 2022-07-27 |
| 2021-03-31 | $55.05M 10-Q · filed 2022-05-05 | $66.08M derived: sum of 2 quarters · filed 2022-05-05 | $36.71M derived: sum of 3 quarters · filed 2022-05-05 | $83.41M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $11.03M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | -$18.34M derived: sum of 2 quarters · filed 2022-03-17 | $28.36M derived: sum of 3 quarters · filed 2022-03-17 | $50.28M 10-K/A · filed 2022-03-17 |
| 2020-09-30 | -$29.37M 10-Q · filed 2021-10-27 | $17.33M derived: sum of 2 quarters · filed 2021-10-27 | $39.24M 10-Q · filed 2021-10-27 | $39.24M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-06-30 | $46.70M 10-Q · filed 2021-07-29 | $68.61M 10-Q · filed 2021-07-29 | $68.61M derived: sum of 3 quarters · filed 2022-03-17 | $68.61M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-03-31 | $21.91M 10-Q · filed 2021-04-28 | $21.91M derived: sum of 2 quarters · filed 2022-03-17 | $21.91M derived: sum of 3 quarters · filed 2022-03-17 | $21.91M derived: sum of 4 quarters · filed 2022-03-17 |
| 2019-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $0.00 derived: sum of 3 quarters · filed 2022-03-17 | $0.00 10-K/A · filed 2022-03-17 |
| 2019-09-30 | $0.00 10-Q · filed 2020-10-28 | $0.00 derived: sum of 2 quarters · filed 2020-10-28 | $0.00 10-Q · filed 2020-10-28 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-07-29 | $0.00 10-Q · filed 2020-07-29 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-04-29 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |